Sodium Valproate as an Adjunctive Drug in Treatment of Schizophrenia

AUTHORS

Victoria Omranifard 1 , * , Afsaneh Karbasi Amel 2 , Siamak Amanat 2

1 Assistant professor of psychiatry, Isfahan Medical University P.O.Box : 81465-993, Isfahan, Iran

2 Department of Psychiatry, Research Center of Psychiatry and Behavioral Sciences, Isfahan, Iran

How to Cite: Omranifard V, Karbasi Amel A, Amanat S. Sodium Valproate as an Adjunctive Drug in Treatment of Schizophrenia, Iran J Psychiatry Behav Sci. 2007 ; 1(1):12-5.

ARTICLE INFORMATION

Iranian Journal of Psychiatry and Behavioral Sciences: 1 (1); 12-5
Published Online: January 30, 2007
Article Type: Original Article
Received: November 22, 2006
Accepted: December 03, 2006

Crossmark

CHEKING

READ FULL TEXT
Abstract

Objective: Although sodium valproate came to the market as an anticonvulsant drug, nowadays it's wildly used in the management of psychiatric disorders. It is used as a mood stabilizer and as an adjunctive agent in treatment of depression and psychosis. There are controversies regarding sodium valproate efficacy in psychosis. Although some studies have reported that it is effective in the management of positive symptoms and aggression in acute psychosis, others have not found such an association. Our study aims to investigate the effects of adjunctive sodium valproate in the pharmacological management of patients with schizophrenia.

Method: In a double blind clinical trial, 32 schizophrenic patients (age 18 65), who were in immediate need of admission, were randomly allocated into two groups. The first group was treated by combination of sodium valproate and risperidone and the other by combination of placebo and risperidone. A diagnosis of schizophrenia was established based on DSM-IV-TR criteria. All patients were assessed by PANSS on the 1 st , 14th and 28th days of the admission. The collected data were analyzed by Student and Paired T tests through SPSS.

Results: Comparison of PANSS mean score in two groups, before and after the trial, showed statistically significant differences. The reduction in PANSS score was significantly higher in the group treated with sodium valproate than in placebo group (P= 0.006). Although, there was a statistically significant reduction in positive symptoms in both group after 2 weeks of treatment (P= 0.048), the difference was not significant in the fourth week (P= 0.88)

Conclusion: Our study shows that if used as an adjunct to antipsychotic in the management of acute psychosis, sodium valproate will speed up the recovery of positive symptom

 

 

Keywords

Risperidone Schizophrenia Valproic Acid

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

Full text is available in the PDF.

References

  • 1.

    References are available in the PDF.

  • COMMENTS

    LEAVE A COMMENT HERE: